TY - JOUR AU - Buyse, Marc AU - Burzykowski, Tomasz AU - Saad, Everardo D. PY - 2018 TI - The search for surrogate endpoints for immunotherapy trials JF - Annals of Translational Medicine; Vol 6, No 11 (June 16, 2018): Annals of Translational Medicine Y2 - 2018 KW - N2 - Mushti and colleagues from the Food and Drug Administration (FDA) have used patient-level data from 13 trials comparing immunotherapeutic agents with standard treatment in various cancer types in an attempt to validate objective response (OR) and progression-free survival (PFS) as surrogate endpoints for overall survival (OS) (1). This is an important issue, given the current and future role of immunotherapy in several cancer types. UR - https://atm.amegroups.org/article/view/19685